Recurrent Non-Invasive Breast Tumors May Not Always Be Related to the Primary Lesion; Patients with Recurrent Lesions Genetically Distinct from the Primary Tumor May Require Different Treatment; Results Presented at AACR Annual Meeting

More than 10 percent of cases of recurrent ductal carcinoma in situ (DCIS) of the breast were “de novo” tumors that occurred independently of the primary lesion and had distinct genetic alterations, according to data presented during the AACR Annual Meeting 2022, held April 8-13 in New Orleans. “DCIS is a precancerous lesion that recurs in approximately 25 percent of patients, and half of these recurrences are invasive cancer with potential life-threatening consequences,” said presenter Tanjina Kader, PhD, a postdoctoral researcher at the Peter MacCallum Cancer Centre in Melbourne, Australia.